Previous 10 | Next 10 |
Continuing on its mission of mastering biology to advance human health, 10x Genomics (TXG) to acquire ReadCoor for cash and stock consideration of $350M.The announcement follows acquisition of Stockholm-based CartaNA AB, developers of In Situ RNA analysis technology, in late August.As a resul...
PLEASANTON, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Continuing on its mission of mastering biology to advance human health, 10x Genomics, Inc. (Nasdaq: TXG) today announced that it has entered into a definitive agreement to acquire ReadCoor, Inc., developer of foundational In Situ tec...
10x Genomics, Inc. has performed outstandingly well since the COVID-19 induced lows of March, more than doubling in this time. Further, the price has held up in volatile times, showing a slow and steady path up with no significant declines. However, I recently trimmed my position ...
The following slide deck was published by 10x Genomics, Inc. in conjunction with this Read more ...
PLEASANTON, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced the closing of its public offering of 4,600,000 shares of its Class A common stock, which included the exercise in full of the underwriters’ option to...
PLEASANTON, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it has begun shipping its Chromium Single Cell Multiome ATAC + Gene Expression solution to customers, marking the first commercial release of a product capable of simultaneously profiling t...
10x Genomics (NASDAQ: TXG ) has priced upsized public offering of its 4M (from 3.5M) Class A common stock at $110.00/share, at a discounted price from Sept. 10 close of $113.51. More news on: 10x Genomics, Inc., Healthcare stocks news, , Read more ...
PLEASANTON, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced the pricing of an upsized underwritten public offering by the Company of its Class A common stock at a price to the public of $110.00 per share, before under...
10x Genomics (NASDAQ: TXG ) has commenced an underwritten public offering of 3.5M shares and underwriters have an option to purchase up to 525k additional shares. More news on: 10x Genomics, Inc., Healthcare stocks news, , Read more ...
PLEASANTON, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced that the Company has commenced an underwritten public offering of 3,500,000 shares of the Company’s Class A common stock to be issued by the Company p...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:00:09 ET Kyle Mikson from Canaccord Genuity issued a price target of $32.00 for TXG on 2024-07-23 05:09:00. The adjusted price target was set to $32.00. At the time of the announcement, TXG was trading at $18.11. The overall price target consensus is at $24...
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report fi...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...